Quick Takeaways
- Rajeev M. Shah has 12 issuer positions tracked on this page.
- Estimated disclosed ownership value: $484,355,249.
- Recent insider filing activity is available below.
Insider Trading & Ownership of Rajeev M. Shah
- Location
- Boston, MA
- Summary
- The estimated net worth of Rajeev M. Shah is at least $484,355,249 dollars as of 08 Jun 2023. Rajeev M. Shah is the Director, 10%+ Owner of Wave Life Sciences Ltd. and owns shares of Wave Life Sciences Ltd. (WVE) stock worth about $175.34M. Rajeev M. Shah is the Director of Mineralys Therapeutics, Inc. and owns shares of Mineralys Therapeutics, Inc. (MLYS) stock worth about $140.74M. Rajeev M. Shah is the Director of Kala Pharmaceuticals, Inc. and owns shares of KALA BIO, Inc. (KALA) stock worth about $73.56M. Rajeev M. Shah is the Director, 10%+ Owner of Vor Biopharma Inc. and owns shares of Vor Biopharma Inc. (VOR) stock worth about $37.88M. Rajeev M. Shah is the Director, 10%+ Owner of Acrivon Therapeutics, Inc. and owns shares of Acrivon Therapeutics, Inc. (ACRV) stock worth about $28.45M. Rajeev M. Shah is the 10%+ Owner of Prelude Therapeutics Inc and owns shares of Prelude Therapeutics Inc (PRLD) stock worth about $22.15M. Rajeev M. Shah is the 10%+ Owner of Adicet Bio, Inc. and owns shares of Adicet Bio, Inc. (ACET) stock worth about $6.23M.
- Signature
- /s/ Thomas P. O'Neil as Attorney in Fact for Rajeev M. Shah
- All Insider Reports
- All Insider Reports
Follow Filing Activity
Follow Rajeev M. Shah and return when a new Insider Trading filing changes the record on this page.
This uses the existing product follow flow to surface future filing-backed changes without guessing what they mean.
What Changed
- Largest disclosed position: Wave Life Sciences Ltd. ($175,340,782).
- Past-year value change for that position: +$54,624,378.
Why This Matters
- This page translates Forms 3/4/5 into a quick ownership context before you inspect each transaction row.
- You can cross-check role, issuer, and filing chronology directly against the SEC source.
Source Evidence
Filed on Form 4
See Original Filing
Insider ownership context is sourced from SEC Forms 3, 4, and 5.
Ownership of Rajeev M. Shah
| Symbol | Company | Relationship | Holdings Value | Past Year Net Change | Change % | Report Period |
|---|---|---|---|---|---|---|
| WVE | Wave Life Sciences Ltd. | Director, 10%+ Owner | $175,340,782 | +$54,624,378 | +45% | 26 Mar 2026 |
| MLYS | Mineralys Therapeutics, Inc. | Director | $140,744,587 | +$8,762,797 | +6.6% | 27 Mar 2026 |
| KALA | Kala Pharmaceuticals, Inc. | Director | $73,564,492 | 17 Jun 2021 | ||
| VOR | Vor Biopharma Inc. | Director, 10%+ Owner | $37,881,038 | -$49,415,318 | -57% | 22 Apr 2026 |
| ACRV | Acrivon Therapeutics, Inc. | Director, 10%+ Owner | $28,445,456 | 22 Apr 2026 | ||
| PRLD | Prelude Therapeutics Inc | 10%+ Owner | $22,152,697 | 27 Apr 2026 | ||
| ACET | Adicet Bio, Inc. | 10%+ Owner | $6,226,197 | +$1,603,934 | +35% | 27 Apr 2026 |
| BDTX | Black Diamond Therapeutics, Inc. | Director | 16 May 2023 | |||
| CLYM | Climb Bio, Inc. | Director, 10%+ Owner | 29 Apr 2026 | |||
| COAG | Hemab Therapeutics Holdings, Inc. | Director, 10%+ Owner | 30 Apr 2026 | |||
| STSA | Satsuma Pharmaceuticals, Inc. | Director, 10%+ Owner | 06 Jun 2023 | |||
| SLDB | Solid Biosciences Inc. | Director, 10%+ Owner | 16 Jun 2021 |
Insider Transactions Reported by Rajeev M. Shah:
| Sym | Company | Class | Transaction | % | Value $ | * Price $ | Shares | Shares After | Date | Ownership |
|---|
* An asterisk sign (*) next to the price indicates that the price is likely invalid.